Mayne Pharma Recovers $14.4M in Legal Costs as Cosette Appeal Awaits Judgment
Mayne Pharma Group (ASX: MYX) has received $14,410,714.49 from Cosette Pharmaceuticals, paid in accordance with orders made by the Supreme Court of New South Wales on 29 May 2026. The payment comprises recovery of legal costs, costs associated with the application for costs, and interest—representing another milestone in ongoing litigation that commenced in June 2025.
Mayne Pharma receives $14.4 million in legal costs from Cosette
The $14.4 million payment follows a Supreme Court judgment delivered in October 2025 that dismissed all of Cosette’s claims and ordered the company to pay Mayne Pharma’s legal costs. The dispute relates to Cosette’s purported termination of a Scheme Implementation Deed signed between the two parties in February 2025.
Mayne Pharma commenced proceedings against Cosette in June 2025 after the latter attempted to terminate the agreement. The Court delivered judgment in favour of Mayne Pharma in October 2025, making an adverse costs order against Cosette requiring it to pay Mayne Pharma’s costs as agreed or assessed.
The payment represents another successful milestone in the proceedings and validates the company’s legal position at the trial level. However, the matter is not yet concluded—Cosette filed an appeal against the October 2025 judgment in January 2026, with the Court of Appeal hearing held on 2-3 June 2026.
When big ASX news breaks, our subscribers know first
Timeline of the Cosette dispute
| Date | Event |
|---|---|
| February 2025 | Scheme Implementation Deed signed between Mayne Pharma and Cosette |
| June 2025 | Mayne Pharma commenced proceedings against Cosette’s purported termination of the Deed |
| October 2025 | Court delivered judgment dismissing all of Cosette’s claims and ordered adverse costs against Cosette |
| January 2026 | Cosette filed an appeal against the October 2025 judgment |
| 29 May 2026 | Court ordered Cosette to pay costs |
| 2-3 June 2026 | Appeal heard in the Court of Appeal; decision reserved |
| 5 June 2026 | Payment of $14,410,714.49 received from Cosette |
The timeline provides investors with clear visibility on where proceedings currently stand and what remains outstanding: the Court of Appeal decision on Cosette’s appeal.
What is an adverse costs order?
In Australian litigation, the losing party is typically ordered to pay the winning party’s legal costs. This is known as an adverse costs order.
The payment received by Mayne Pharma represents the costs recovery awarded following the October 2025 judgment. However, receiving this payment does not conclude the matter—Cosette has appealed the underlying judgment and a decision on that appeal is pending.
The adverse costs order demonstrates the strength of Mayne Pharma’s legal position as assessed by the Supreme Court at the trial level. The Court found in favour of Mayne Pharma, dismissing all of Cosette’s claims and ordering costs against the company. This validates the company’s litigation strategy, though the appeal outcome remains uncertain.
The court award against Cosette totalled $13,269,328.04 in assessed legal costs at first instance, with the additional interest component and costs of the costs application bringing the final received amount to $14,410,714.49.
What comes next for Mayne Pharma
The Court of Appeal heard Cosette’s appeal on 2-3 June 2026. A decision has been reserved, meaning the judges have taken time to deliberate and will deliver judgment at a later date.
There is no stated timeline for when this decision will be handed down. Court of Appeal decisions can take several months depending on the complexity of the matter and the court’s schedule.
The original dispute relates to Cosette’s purported termination of the Scheme Implementation Deed signed in February 2025. The appeal outcome will determine whether the October 2025 judgment stands or is overturned—investors should monitor for the Court of Appeal decision as a material event.
The next major ASX story will hit our subscribers first
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women’s health in the United States. The company also provides contract development and manufacturing services to clients worldwide, with a 40-year track record of innovation in oral drug delivery systems.
What Does This Legal Victory Mean for Mayne Pharma’s Future?
The $14.4 million payment validates Mayne Pharma’s legal strategy and strengthens its financial position whilst the Court of Appeal deliberates on Cosette’s challenge. However, with the appeal decision still pending, investors should remain alert to potential developments that could materially impact the company’s trajectory.
To stay updated on the Court of Appeal outcome and Mayne Pharma’s broader strategic initiatives, visit the Mayne Pharma investor centre for comprehensive coverage of all material announcements.